IPO Anatomy of a Successful 2026 Listing: What City Therapeutics Got Right
City Therapeutics priced its Nasdaq IPO at the $18 midpoint, upsized to $200 million and closed up 28%. Andy Altahawi on the four structural choices behind the debut, and how smaller issuers can copy them.
